In another retrospective study of patients with non-metastatic solid tumors (including breast) or NHL receiving high or intermediate FN risk chemotherapy regimens, the incidence of FN in the first cycle ranged from 2.2–3.8% in patients who received G-CSF prophylaxis [19]. Here, CSF3 is linked to non-Hodgkin lymphoma.